Biological variation of plasma F2-isoprostane-III and arachidonic acid in healthy individuals.

bladder cancer risk. Cancer Res 1991;51:2762–7. 19. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998;4:535–8. 20. Mostofi FK, Sobin LH, Torloni H. Histologic typing of urinary bladders. In: International histological classification of tumors. Geneva: World Health Organization, 1973:36. 21. Spiessl B, Beahrs OH, Hermanek P, Hutter RV, Scheibe O, Sobin LH. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumors, 3rd ed., 2nd revision. Berlin: Springer-Verlag, 1992:274–9. 22. de Kok JB, van Balken MR, Roelofs RW, van Aarssen YA, Swinkels DW, Klein Gunnewiek JM. Quantification of hTERT mRNA and telomerase activity in bladder washings of patients with recurrent urothelial cell carcinomas. Clin Chem 2000;46:2003–7. 23. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. SurvivinEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097–102. 24. Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res 1998;4:3011–6.